We are live on ! Find out more
ELTX icon

Elicio Therapeutics
ELTX

30 hedge funds and large institutions have $3.98M invested in Elicio Therapeutics in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.07% less ownership

Funds ownership: 1.7% → 1.63% (-0.07%)

15% less capital invested

Capital invested by funds: $4.71M → $3.98M (-$723K)

21% less funds holding

Funds holding: 38 → 30 (-8)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 8

Holders
30
Holders Change
-8
Holders Change %
-21.05%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
6
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CM
CM Management
Florida
+$120K
2
UBS Group
UBS Group
Switzerland
+$2.44K
3
BlackRock
BlackRock
New York
+$1.08K
4
TRCT
Tower Research Capital (TRC)
New York
+$1.03K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$618

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$79.3K
2
Millennium Management
Millennium Management
New York
-$45.7K
3
NCM
Nantahala Capital Management
Connecticut
-$29.9K
4
VFA
Valeo Financial Advisors
Indiana
-$24.3K
5
E
Ergoteles
New York
-$23.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$869K – – –
NCM
2
Nantahala Capital Management
Connecticut
$839K -$29.9K -3,286 -3%
CM
3
CM Management
Florida
$594K +$120K +13,218 +22%
Vanguard Group
4
Vanguard Group
Pennsylvania
$523K +$618 +68 +0.1%
PWAM
5
Park West Asset Management
California
$301K – – –
BCM
6
Bridgeway Capital Management
Texas
$142K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$136K -$409 -45 -0.3%
Renaissance Technologies
8
Renaissance Technologies
New York
$99K -$79.3K -8,728 -42%
Millennium Management
9
Millennium Management
New York
$61K -$45.7K -5,026 -40%
RJA
10
Raymond James & Associates
Florida
$48.7K – – –
BlackRock
11
BlackRock
New York
$44.9K +$1.08K +119 +2%
BC
12
Birchview Capital
Vermont
$44K – – –
E
13
Ergoteles
New York
$42.9K -$23.6K -2,595 -33%
CC
14
Cannell Capital
Wyoming
$32.6K – – –
VFA
15
Valeo Financial Advisors
Indiana
$30K -$24.3K -2,671 -42%
Prudential Financial
16
Prudential Financial
New Jersey
$27.9K – – –
Northern Trust
17
Northern Trust
Illinois
$27.4K – – –
Acadian Asset Management
18
Acadian Asset Management
Massachusetts
$19K – – –
PFGIA
19
Patriot Financial Group Insurance Agency
Massachusetts
$17.4K -$13.6K -1,500 -41%
Bank of America
20
Bank of America
North Carolina
$16.5K -$8.99K -989 -33%
CG
21
Caprock Group
Idaho
$12.8K – – –
SPIA
22
Steward Partners Investment Advisory
New York
$12.6K – – –
BBA
23
BLB&B Advisors
Pennsylvania
$12.6K -$6.81K -750 -33%
State Street
24
State Street
Massachusetts
$10.3K – – –
UBS Group
25
UBS Group
Switzerland
$8.04K +$2.44K +268 +37%
1
2

ELTX Hedge Fund Activity: Q4 2022 in Review

30 of the 6,224 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q4 2022, worth a combined $3.98M — down 15% from $4.71M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ELTX and 0 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 6 added.

The largest buyer was CM Management, adding an estimated $120K. The largest seller was Renaissance Technologies, cutting an estimated $79.3K.

  • 30 institutional investors held Elicio Therapeutics (ELTX) as of Q4 2022, down from 38 in Q3 2022.
  • Funds reported $3.98M of Elicio Therapeutics stock for Q4 2022, down 15% quarter-over-quarter.
  • 0 funds opened new Elicio Therapeutics positions in Q4 2022 and 8 closed out, a net change of -8 holders.
  • The largest Elicio Therapeutics buyer in Q4 2022 was CM Management, an estimated $120K added.
  • The largest Elicio Therapeutics seller in Q4 2022 was Renaissance Technologies, an estimated $79.3K sold.

Based on aggregated 13F filings for Q4 2022.